Sugi Predict

Sugi Predict / Compounds / SCHEMBL2712980

SCHEMBL2712980

SCHEMBL2712980

O=C(O)[C@@H]1CCC(c2ccc(OCc3ccccc3F)cc2)=N1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 4/20 0.49
▸ PARP15 Q460N3 1/20 0.49
▸ PARP14 Q460N5 1/20 0.49
▸ PARP10 Q53GL7 1/20 0.49
▸ LPAR1 Q92633 3/20 0.48
▸ LPAR5 Q9H1C0 3/20 0.48
▸ SCN3A Q9NY46 7/20 0.47
▸ KCNH2 Q12809 7/20 0.47
▸ SCN1A P35498 1/20 0.47
▸ SCN4A P35499 1/20 0.47
▸ SCN7A Q01118 1/20 0.47
▸ SCN5A Q14524 1/20 0.47
▸ SCN9A Q15858 1/20 0.47
▸ SCN2A Q99250 1/20 0.47
▸ SCN8A Q9UQD0 1/20 0.47
▸ SCN10A Q9Y5Y9 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP2B6 P20813 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ FFAR2 O15552 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22534101 1.00 MAOB (0.49) MAOBPARP15PARP14PARP10LPAR1
SCHEMBL22534112 0.90 SCN3A (0.54) MAOBPARP15PARP14PARP10LPAR1
SCHEMBL13320301 0.90 MAOB (0.54) MAOBPARP15PARP14PARP10LPAR1
SCHEMBL22534110 0.90 SCN3A (0.54) MAOBPARP15PARP14PARP10LPAR1
SCHEMBL22546709 0.88 MAOB (0.49) MAOBPARP15PARP14PARP10LPAR1
SCHEMBL310302 0.88 MAOB (0.49) MAOBPARP15PARP14PARP10LPAR1
SCHEMBL29385120 0.88 MAOB (0.49) MAOBPARP15PARP14PARP10LPAR1
SCHEMBL2832345 0.87 MAOB (0.50) MAOBPARP15PARP14PARP10LPAR1
SCHEMBL2837133 0.87 KCNH2 (0.53) MAOBPARP15PARP14PARP10LPAR1
SCHEMBL12079894 0.86 MAOB (0.47) MAOBPARP15PARP14PARP10LPAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220177426-A1 PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES BIOGEN MA INC. 2022-06-09 — — US disclosed
EP-3953329-A1 PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES Biogen MA Inc. (US) 2022-02-16 — — EP disclosed
CN-114026066-A Process for preparing alpha-carboxamide pyrrolidine derivatives 生物基因麻省公司 2022-02-08 — — CN disclosed
US-20210154170-A1 METHODS OF TREATING NEUROPATHIC PAIN BIOGEN MA INC. 2021-05-27 — — US disclosed
WO-2020210485-A1 PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES BIOGEN MA INC. (US) 2020-10-15 — — WO disclosed
EP-2461807-A1 CO-THERAPY FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS Convergence Pharmaceuticals Limited (GB) 2012-06-13 — — EP disclosed
EP-1934177-B1 PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS GLAXO GROUP LTD (GB) 2012-05-02 — — EP disclosed
US-20100324022-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-12-23 — — US disclosed
US-7855218-B2 (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide; depression or a mood disorder ; modulation of use-dependent voltage-gated sodium channels Convergence Pharmaceuticals Limited (GB) 2010-12-21 — — US disclosed
US-7803833-B2 Compounds GLAXO GROUP LIMITED (GB) 2010-09-28 — — US disclosed
WO-2008090117-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 3, 5-DIAMIN0-6- (2, 3-DICHL0PHENYL) -L, 2, 4-TRIAZINE OR R (-) -2, 4-DIAMINO-5- (2, 3-DICHLOROPHENYL) -6-FLUOROMETHYL PYRIMIDINE AND AN NK1 GLAXO GROUP LIMITED (GB) 2008-07-31 — — WO disclosed
WO-2008090116-A1 NOVEL PHARMACEUTICAL COMPOSITIONS GLAXO GROUP LIMITED (GB) 2008-07-31 — — WO disclosed
WO-2008090114-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5- (5-TRIFLUOROMETHYL-TETRAZOL-I-YL-BENZYL) - (2S-PHENYL-PIPERIDIN-3S-YL-) GLAXO GROUP LIMITED (GB) 2008-07-31 — — WO disclosed
WO-2008090115-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2008-07-31 — — WO disclosed
EP-1943216-A1 PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS GLAXO GROUP LIMITED (GB) 2008-07-16 — — EP disclosed
EP-1934176-A1 QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS GLAXO GROUP LIMITED (GB) 2008-06-25 — — EP disclosed
EP-1934177-A1 PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS GLAXO GROUP LIMITED (GB) 2008-06-25 — — EP disclosed
WO-2007042239-A1 PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS GLAXO GROUP LIMITED (GB) 2007-04-19 — — WO disclosed
WO-2007042240-A1 QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS GLAXO GROUP LIMITED (GB) 2007-04-19 — — WO disclosed
WO-2007042250-A1 PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS GLAXO GROUP LIMITED (GB) 2007-04-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324022-A1 NOVEL COMPOUNDS CYP46A1, NPC1, CYP11B1 MAOB 1344/4885PARP15 2566/4885PARP14 2597/4885
US-20220177426-A1 PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES CPS1, PCCA, ALDH18A1 MAOB 114/4885PARP15 56/4885PARP14 226/4885
US-20210154170-A1 METHODS OF TREATING NEUROPATHIC PAIN OPRL1, PMP22, PRPH MAOB 1203/4885PARP15 3364/4885PARP14 3595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.